Otsuka Corporation (TYO:4768)
Japan · Delayed Price · Currency is JPY 3,017.00
+17.00 (0.57%)
Nov 17, 2025, 3:30 PM JST
Otsuka Revenue
Otsuka had revenue of 310.59B JPY in the quarter ending September 30, 2025, with 22.99% growth. This brings the company's revenue in the last twelve months to 1.29T, up 21.85% year-over-year. In the year 2024, Otsuka had annual revenue of 1.11T with 13.33% growth.
Revenue (ttm)
1.29T
Revenue Growth
+21.85%
P/S Ratio
0.88
Revenue / Employee
133.38M
Employees
9,680
Market Cap
1.14T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.11T | 130.30B | 13.33% |
| Dec 31, 2023 | 977.37B | 116.35B | 13.51% |
| Dec 31, 2022 | 861.02B | 9.13B | 1.07% |
| Dec 31, 2021 | 851.89B | 15.57B | 1.86% |
| Dec 31, 2020 | 836.32B | -50.21B | -5.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sony Group | 13.15T |
| NEC Corporation | 3.51T |
| Fujitsu | 3.42T |
| Tokyo Electron | 2.49T |
| TDK Corporation | 2.30T |
| Murata Manufacturing | 1.76T |
| Nintendo | 1.74T |
| Kioxia Holdings | 1.59T |
Otsuka News
- 17 days ago - Otsuka 9-month Profit Rises; Revenue Up 5.1% - Nasdaq
- 4 months ago - Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting - Seeking Alpha
- 4 months ago - SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka - Benzinga
- 5 months ago - Vera plunges as Otsuka outperforms with IgA nephropathy therapy - Seeking Alpha
- 6 months ago - Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) - Benzinga
- 8 months ago - Arbitrum DAO mulls winding down unsustainable Web3 gaming fund - Cointelegraph
- 9 months ago - Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
- 9 months ago - Vera plunges as Otsuka updates on rival therapy - Seeking Alpha